MLAB CFO John Sakys Sells Shares
John Sakys sold 2,717 shares of MLAB on June 15, 2026.
Key Points
- John Sakys, CFO of MLAB, sold 2,717 shares on June 15, 2026, with the stock trading at $104.08.
- MLAB's stock is trading around $104.08 with various institutional investors adjusting their positions.
- Wells Fargo maintained a 'hold' rating for MLAB on February 4, 2026, with a price target of $94.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 15, 2026, John Sakys, the Chief Financial Officer of MLAB, sold 2,717 shares of the company. The transaction occurred at a trading price of $104.08 per share. Sakys's sale was not part of a pre-arranged trading plan.
Insider Buying and Selling at Mesa Laboratories, Inc.
John Sakys, MLAB's CFO, conducted multiple transactions on June 15, 2026. Besides selling 2,717 shares, he also sold 3,951 shares in another transaction. Meanwhile, Brian David Archbold, Senior Vice President of Operations, sold 1,780 shares and 2,454 shares in separate transactions on the same day.
Other Institutional Activity in MLAB
Several institutional investors have been active in MLAB recently. Long Path Partners LP significantly increased its holdings, adding 178,360 shares to reach a total of 405,583 shares valued at approximately $35.9 million. BlackRock, Inc. slightly reduced its position by 4,815 shares, ending with 393,851 shares worth about $34.8 million. Boston Partners, however, increased its stake by 55,335 shares, bringing its total to 268,711 shares valued at roughly $23.8 million.
Mesa Laboratories, Inc. Stock Down 19.3%
Shares of MLAB are trading around $104.08. The stock's performance includes a 52-week range, a 50-day moving average, and a 200-day moving average, though specific values were not detailed. Investors keep a close watch on these metrics to gauge the stock's volatility and potential future movements.
$MLAB stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
Wells Fargo maintained its 'hold' rating for MLAB on February 4, 2026, with a price target of $94. This follows a series of ratings adjustments by Wells Fargo over the past year, reflecting varied assessments of the stock's potential. Evercore ISI has consistently maintained a 'buy' rating, with its most recent target set at $106.
About MLAB
MLAB operates in the [sector/industry] and is known for [brief description of what it does]. The company is headquartered in [location] and managed by CEO [name]. With [number of employees] employees, MLAB continues to [further description of operations or goals].
Bottom Line
The recent insider transactions at MLAB, including those by CFO John Sakys, highlight ongoing activity within the company. Investors often track such moves to gain insights into potential future performance. However, it's essential to remember that these transactions reflect past activity and may not indicate current or future strategies.
Get Mesa Laboratories, Inc. alerts
New 13F filings, insider trades, and analyst moves on $MLAB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.